Innovate Biopharmaceuticals, Inc. announced Dr. June Almenoff has been appointed Chief Operating Officer and Chief Medical Officer. Dr. Almenoff brings a strong track record of success in biopharma leadership. Dr. Almenoff was previously President and Chief Medical Officer at Furiex Pharmaceuticals, where during her 4-year tenure the company valuation increased 10-fold, culminating in its acquisition by Actavis plc for more than $1.2 billion in 2014. Furiex lead product, eluxadoline, a novel gastrointestinal drug, is approved in both the US and EU. Prior to joining Furiex, Dr. Almenoff held various positions of increasing responsibility at GlaxoSmithKline PLC.